Successful Revascularization of Acute Middle Cerebral Artery Occlusion by Intravenous Thrombolysis While on Apixaban
Sir, A 60-year-old hypertensive female taking low-dose apixaban for atrial fibrillation and prior stroke came with acute right hemiparesis and aphasia of 150 min duration while undergoing ayurvedic treatment. Her National Institutes of Health Stroke Scale (NIHSS) score was 16 and blood pressure was 170/100 mmHg. The last dose of apixaban was taken 13 h before admission. Emergency computed tomography (CT) brain showed a hyperdense middle cerebral artery (MCA) sign with Alberta Stroke Program Early CT score of 7 [ Figure 1a ]. Her activated partial thromboplastin time and prothrombin time at the emergency was within normal range; thrombin time and anti-factor Xa activity assays were not available. She was given intravenous thrombolysis after discussing the risks with the available family member and caretaker. Tissue plasminogen activator was started by 200 min from onset with a door to needle time of 50 min. NIHSS score dropped 8 points in 2 h with improvement in motor scores. A repeat CT brain showed disappearance of the hyperdense MCA with a left frontotemporal infarct [ Figure 1b ]. The patient was started on aspirin after the 24 h CT scan which showed no evidence of bleeding. Mild word finding issues persisted. She was discharged after 5 days with low-dose apixaban which was later changed to full dose after a repeat CT taken at day 14. She was counseled well regarding the dose and schedule of apixaban and is under follow-up with no deficits.
As more patients are on newer oral anticoagulants (NOACs) for secondary prevention, identification of the right candidate for intravenous thrombolysis can be a challenge. Although guidelines suggest mechanical thrombectomy as the primary treatment and do not warrant intravenous thrombolysis for patients on NOACs, inadequate endovascular facilities make intravenous thrombolysis relevant. The emergency facilities to do anti-factor Xa activity, thrombin time, or ecarin clotting time are not available in most of the centers. Routine coagulation tests will not predict the accurate biological activity of the NOACs. [1] However, a normal baseline coagulation profile can rule out a major overdosage. Of the NOACs, apixaban has a bleeding risk comparable to aspirin. [2] Animal studies in rats showed less hemorrhagic transformation of infarct in rivaroxaban or apixaban pretreated rats compared to warfarin pretreated rats due to the reduced matrix metalloproteinase (MMP-9) expression by the anti-factor Xa inhibitors. [3] Another multicenter observational cohort study reported that the patients on NOACs who underwent revascularization with intravenous thrombolysis for an acute ischemic stroke have a safety profile compared to when used in patients on subtherapeutic Vitamin K antagonist treatment or in those not on any anticoagulation. [4] This case adds to this point that apixaban-treated patients can also be candidates for thrombolysis. A subgroup of patients with low drug levels could be eligible for thrombolysis, but identifying these patients at the emergency setting is difficult. A point of care device for the detection of three NOACs in emergency was feasible in a recent study. [5] Many patients might have missed a single dose and could be exposed to risk of stroke. Significant drug or food interaction of factor Xa inhibitors due to intestinal P glycoprotein (P-gp) inhibition while taking ayurvedic medications containing phytates and Sir, We read the findings by Adwani et al. [1] with great interest. Differences in motor [2] as well as nonmotor [3] manifestations of Parkinson's disease (PD) have been observed in right-sided (R-PD) versus left-sided (L-PD) disease. However, some of these associations have been debated in the literature.
We recently recruited a number of PD patients (n = 31) as part of an ongoing neurocognitive study. The onset of PD was on the right in 16 patients and on the left in 15 patients. Both groups were of similar age (R-PD mean 65.5 years; L-PD mean 68.7 years) and male-to-female ratio (R-PD 75% males; L-PD 87% males). All patients were on dopamine replacement therapy.
Handedness was assessed by the Edinburgh handedness inventory. [4] Except one patient who was ambidextrous, all patients were right handed. We assessed whether handedness-symptomatic side mismatch (i.e., left-sided symptom onset in a right-handed individual) who delay the interval between symptom onset and diagnosis. R-PD patients were diagnosed 2.1 (±1.0) years after symptoms onset, compared with 1.6 (±0.8) years in L-PD patients; this difference was not statistically significant (P = 0.15).
Mild cognitive impairment was equally distributed between R-PD (50%) and L-PD (53%) patients. Disease duration was similar between the two groups: 6.3 (±3.5) years for R-PD and 8.3 (±5.3) years for L-PD (P = 0.23). The extent of motor deficit was not different between the two groups as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS-II) (14.7 vs. 17.3, P = 0.39, respectively) and the UPDRS-III (31.6 vs. 38.6, P = 0.13, respectively). The severity of symptoms of anxiety and depression (as assessed by the Hospital Anxiety and Depression Scale) was also similar between R-PD (mean 9.9 points) and L-PD (mean 9.7 points) patients (P = 0.95).
In conclusion, we found no difference in R-PD versus L-PD patients in relation to motor or psychological symptoms in our sample. Further insights may be obtained by comparing drug-naïve versus medicated PD patients as well as inclusion of PD patients with established PD-dementia.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
